Free Trial
LON:SALV

SalvaRx Group (SALV) Share Price, News & Analysis

About SalvaRx Group Stock (LON:SALV)

Key Stats

Today's Range
N/A
50-Day Range
4.50
4.50
52-Week Range
N/A
Volume
50,758 shs
Average Volume
50,758 shs
Market Capitalization
£1.65 million
P/E Ratio
0.03
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

SalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man.

Receive SALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SalvaRx Group and its competitors with MarketBeat's FREE daily newsletter.

SALV Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

SALV Stock Analysis - Frequently Asked Questions

Shares of SALV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that SalvaRx Group investors own include Premier African Minerals (PREM), Cradle Arc (CRA), Cora Gold (CORA), Big Sofa Technologies Group (BST), Bahamas Petroleum (BPC), Bacanora Lithium (BCN) and AutoZone (AZO).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£64.50 million
Book Value
GBX 15.40 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.65 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (LON:SALV) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners